Toll-like receptors (TLRs) are a crucial component of the innate immune system and are involved in the pathophysiology of a wide range of hepatic and other diseases [1] [2] [3] [4] [5] . They are a family of non-clonal, germlineencoded pattern recognition receptors which recognize distinct sequences on microbial pathogens to trigger a rapid immune response [6] [7] [8] . Activation results in production of proinflammatory cytokines and, for some TLRs, type-1 interferons via complex intracellular signalling pathways including several adaptor molecules. This system has also been found to be important in inducting and regulating the adaptive immune response via expression of co-stimulatory molecules on antigenpresenting cells [6, 9, 10] .
Specific TLRs can bind a wide variety of specific bacterial, fungal, and protozoal components and provide the innate immune system with considerable specificity [8, 11] . For example, TLR3 recognizes double-stranded RNA and TLR7 and TLR8 bind to single-stranded RNA from viruses. TLR9 detects unmethylated CpG-containing DNA from viruses and bacteria. TLR2 and TLR4 are generally regarded as the pattern recognition receptors for Gram-positive ( peptidoglycan) and Gram-negative (LPS) bacteria, respectively, although they have also been shown to play a role in some viral infections, hepatic responses to injury and recognition of endogenous ligands released at times of cellular stress. TLRs are also compartmentalized to facilitate their specific roles with receptors that mainly recognize viral products (TLR3, TLR7/8 and TLR9) located intracellularly in the endosome-lysosome where viral RNA is processed and where host DNA is not present to avoid erroneous stimulation [10] .
Several TLRs are involved in the pathophysiology of viral infections, such as hepatitis B and C. These viruses induce antiviral responses via TLR recognition and stimulation. However, both hepatitis B and C are also able to manipulate or directly impair TLR signalling in order to evade clearance and promote chronic infection.
Several single nucleotide polymorphisms (SNPs) of TLRs have been demonstrated to be functionally significant with impaired or altered cytokine responses [12] [13] [14] [15] [16] [17] [18] . A number of commonly identified TLR SNPs have been
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implicated in a wide range of human diseases including viral hepatitis [13, [18] [19] [20] [21] [22] [23] [24] [25] . Furthermore, genetic variants downstream of TLR activation, including signalling molecules and cytokines, may also alter the risk of various infectious diseases [26] [27] [28] .
The purpose of this review is to summarize the role polymorphisms of TLRs and TLR-mediated pathways might play in the response to and outcomes from viral hepatitis, focusing particularly on acute and chronic hepatitis B and C infection.
HBV
TLRs and chronic HBV
There is substantial evidence for an important role for the TLR-mediated innate immune system in chronic HBV infection. It has been suggested that HBV contains TLR ligands and induces cytokine production via the TLR2 signalling pathway [29] . There are also studies indicating that TLR signalling can restrict HBV replication. For example, in the HBV-transgenic mouse model, administration of specific ligands for TLR3, TLR4, TLR5, TLR7 and TLR9 resulted in prompt and significant inhibition of viral replication in an interferon-dependent manner [30] . Furthermore, stimulation of HBV-transfected hepatocyte cell lines with TLR2 ligands has been demonstrated to inhibit HBV replication [31] . Supernatants from murine non-parenchymal liver cells have also been shown to suppress HBV replication after stimulation with TLR3 and TLR4 [32] .
Further in vitro and ex vivo studies have suggested a role for HBV-specific mechanisms in targeting TLRs to escape immune control. Chen et al. [33] investigated TLR1-10 expression in chronic HBV and demonstrated significant down-regulation of TLR1, TLR2, TLR4 and TLR6 in peripheral blood mononuclear cells (PBMCs) in patients with HBV compared with healthy controls. This study also observed impaired cytokine production in response to TLR2 and TLR4 ligands in PBMCs from HBV patients. Our laboratory has demonstrated downregulation of TLR2 on hepatocytes, Kupffer cells and PBMCs in hepatitis B e antigen (HBeAg)-positive patients when compared to patients with HBeAg-negative hepatitis and healthy controls [34, 35] . In HBeAg-negative patients, there was significantly increased TLR2 expression and tumour necrosis factor (TNF)-α production suggesting the precore protein may mediate downregulation of TLR-dependent innate immune responses during the HBeAg-positive phase of chronic HBV.
Other studies have described the role of other TLRs in chronic HBV, including decreased TLR3 expression on monocyte-derived dendritic cells, decreased TLR9 expression on plasmacytoid dendritic cells and inhibition of TLR9-mediated interferon-α production by plasmacytoid dendritic cells treated with heptatitis B surface antigen (HBsAg) [36] [37] [38] . In addition, ligands for TLR7 and TLR9 have been found to augment cellular and humoral immune responses when used as adjuvants to HBsAg vaccination [39] [40] [41] .
Therefore the ability of HBV to evade immune surveillance and establish persistent infection relies on interaction with TLR pathways and appears to involve direct suppression by HBV antigens. Furthermore, TLR agonists might hold promise in future therapies or vaccination against HBV. It could be expected that SNPs affecting TLRs important for the innate immune response to HBV could have functional and clinical significance in these patients.
However, there is very little data examining the role of TLR SNPs in chronic HBV. A single study involving the Chinese Han population attempted to investigate the association of two commonly studied functionally impaired TLR4 mutations (Asp299Gly and Thr399Ile) and HBV-related cirrhosis, but did not detect any TLR4 mutations in either cirrhotics or healthy controls in this patient group [42] . A further recent study, again in the Chinese Han patients, found another polymorphism in the TLR4 gene (rs11536889) that might be associated with recurrence of HBV after liver transplantation, although the mechanism is unclear [43] . These limited findings are outlined in Table 1 .
There have been no studies reported to date examining other TLR SNPs or other populations with HBV. Clearly, further investigation is required involving different ethnic populations to confirm the role of TLR SNPs in the pathogenesis and outcomes of chronic HBV.
TLRs and acute HBV
Although innate immune responses are crucial in the initial response to acute viral infection, their role in the early phases of hepatitis B infection has not been completely elucidated. Human studies, in particular, are limited by the difficulty in identifying cases at the generally asymptomatic acute or preclinical stage, with most HBV patients being diagnosed when infection is already established. It has been shown in small human cohorts and animal studies using the chimpanzee model that the early stages of acute HBV infection are characterized by a surprising lack of induction of type I interferon-induced genes, but with an increase in production of the immunosuppressive cytokine interleukin (IL)-10 [44, 45] . There also appears to be rapid innate and adaptive responses to acute HBV with early activation of natural killer (NK) and NKT-cells and HBV-specific T-cell responses [46] . There may be attenuation of these responses at the time of peak viraemia with subsequent peaking, as HBV DNA levels decrease and immune responses can vary with different states of chronic infection [44, 46, 47] . It has also been shown that IL10 can mediate down-regulation of TLR responses including inhibition of type I interferons from plasmacytoid dendritic cells and interferon-γ from NK cells via Kupffer cells [48, 49] .
Animal models of non-viral acute hepatitis also suggest a significant role for TLR-mediated signalling in immune responses and liver injury. For example, in a murine model of concanavalin A-induced hepatitis, both TLR3 and TLR9 signalling have been implicated in mediating liver damage and inflammation [50] [51] [52] . In D-galactosamine-induced acute liver failure models it has been suggested that intrahepatic TLR4 messenger RNA and TNF-α expression are increased but an agonistic antibody to TLR4 is protective from lethal hepatitis via anti-apoptotic signalling [53, 54] . Therefore, it could be expected that TLR-mediated pathways are a crucial component of the immunological changes seen in acute HBV. However, despite the extensive body of literature on the role of TLRs in chronic HBV, there is very little data examining changes in TLR expression or function in acute infection.
In an in vivo murine model of acute HBV, TLR4 was found to play an anti-HBV role with mutant mice displaying impaired HBV-specific immune responses in the liver, impaired inducible nitric oxide synthase expression and higher HBV antigenaemia, replication and transcription [55] . Decreased TLR3 expression and signalling on monocyte-derived dendritic cells has been reported in patients with acute-on-chronic liver failure from HBV, particularly in those with more severe liver damage [37] . Zhang et al. [56] describe accumulation of activated plasmacytoid dendritic cells in the livers of patients with acute-on-chronic HBV liver failure, which may regulate intrahepatic immune responses and cytokine production via TLR9 mediated pathways. However, there are no clinical studies investigating the role of TLRs in acute HBV specifically. There are also no published reports examining any association of TLR polymorphisms and the early phases of HBV infection.
Intracellular pathways and HBV
TLR signalling involves several intracellular signalling adaptor molecules including myeloid differentiation factor 88 (MyD88), Toll/IL1 receptor (TIR) domain containing adaptor protein (TIRAP), TIR-domain containing adaptor inducing interferon-β (TRIF) and TRIF-related adaptor molecule (TRAM) to activate inflammatory and antiviral responses [57] . In HBV, it has been demonstrated that expression of the TLR adaptor proteins MyD88 and TRIF in human hepatoma cells significantly reduces viral replication via nuclear factor-κB-dependent pathways [58] .
Genetic polymorphisms for TIRAP have been described in association with increased susceptibility to infectious complications and found to be functionally relevant with altered cytokine responses [26, 27, [59] [60] [61] . For example, the Ser180Leu, rs8177374 SNP impairs TLR2-mediated signalling and has been shown to be protective against invasive pneumococcal disease, bacteraemia, malaria, tuberculosis and cardiomyopathy from chronic Chagas disease, but associated with a higher risk of severe post-operative infections [27, 59, 62] . Another TIRAP variant, C558T, has been associated with an increased susceptibility to meningeal tuberculosis and decreased IL6 production in Vietnamese patients [26] .
It has been suggested that these SNPs influence the risk of disease by modulating the inflammatory response, particularly of TLR2-and TLR4-mediated responses. However, there have been no reports on an association of any TIRAP SNPs with acute or chronic HBV. Similarly, there have also been no studies of any polymorphisms of the other intracellular signalling molecules (MyD88, TRIF and TRAM) in relation to HBV.
Cytokines and HBV
Activation of TLR signalling results in the production of various cytokines, such as IL10 and TNF-α, which can regulate the immune and inflammatory response. There has also been significant interest in the role functional polymorphisms of cytokines might play in the susceptibility to or outcomes from HBV infection. Table 2 highlights the clinical associations that have been reported with relevant cytokine polymorphisms in HBV although as we describe below, data are inconsistent and lacking in a number of areas.
IL10 has important immunosuppressive and antiinflammatory functions [63] . A number of polymorphisms in the IL10 promoter region have been identified which can affect IL10 production, including variations at positions 1082, 819 and 592, although there is significant linkage disequilibrium between allelic variations [64] . Certain genotypes, such as 592AC, have been associated with persistent infection in Asian but not European patients, whereas the 592CC variant, which is associated with higher IL10 production, has been found more frequently in Asian patients with clearance of HBV infection [65, 66] . Other studies of non-Asian patients have also found no significant association between these IL10 gene polymorphisms and chronic HBV [67] .
However, there is conflicting evidence regarding the role that IL10 gene polymorphisms may play in clinical outcomes from HBV infection. It has been suggested that polymorphisms at positions 1082, 819 and 592 resulting in genotypes or haplotypes associated with low IL10 production are significantly more frequent in asymptomatic carriers with HBV than patients with chronic progressive disease [68] . Additionally, 592AC and 819TC variations, which might be expected to have higher levels of IL10 production, have been associated with susceptibility to HBV-related acute liver failure [69] . However, the high production 1082GG genotype has been found to predict early, spontaneous e antigen seroconversion [70] . Low production genotypes, such as 1082AA, have also been associated with persistent infection and clinical progression and other studies have found no differences between inactive or progressive disease and IL10 gene polymorphisms [66, 71] . Furthermore, variants of IL10 627 associated with high IL10 production were found to be protective Toll polymorphisms and viral hepatitis against severe fibrosis in Chinese patients with chronic HBV [72] . Interestingly, high production genotypes and haplotypes of IL10 627 are much more prevalent in the Caucasian population which may explain the less aggressive disease outcomes in Caucasians compared to other ethnicities [67, 73] .
There appears to be similar controversy regarding the importance of polymorphisms of TNF-α, an important proinflammatory cytokine, in HBV infection. Genetic variations of the TNF-α promoter at positions 238 and 308, which are both associated with increased functional TNF-α production, have been examined in several studies with conflicting results. For example, the 238GG genotype has been associated with persistent infection and self-limited disease in different reports [74] [75] [76] . Polymorphisms at position 238 may also influence response to antiviral therapy with lamivudine [77] . The 308GG genotype has been associated with a risk of decompensated cirrhosis in an Italian study and Asian patients homozygous for the 308G/238G haplotype appeared at higher risk of persistent infection [66, 78] . It has also been suggested that polymorphisms at position 857 are associated with different outcomes in HBV with the 857TT genotype correlated with spontaneous clearance and the 857CC genotype more common in patients with chronic infection [74, 75] . A further study found that variations at position 863 but not 308 or 238 may influence risk of chronic infection and development of hepatocellular cancer [79] . Indeed, there are several further reports suggesting no significant association between TNF-α promoter variations and clinical outcomes from HBV infection [67, 68, 72] .
No significant association between genetic variations of IL6 at positions 174 or 572 and HBV have been found, although studies are limited [67, 80] . Moreover, there are limited reports on the role of polymorphisms in other cytokines typically mediated by TLRs in HBV, although several other cytokines and other immune pathways have been examined and implicated.
The majority of studies examining cytokine polymorphisms in HBV have been association studies and have involved Asian populations. This may account for some of the variability of results, although conflicting data even between cohorts of Asian patients indicates further studies of polymorphisms of relevant cytokines in HBV, including different ethnic populations, are still required to determine their influence on risk of infection or disease progression. In addition, although several cytokine polymorphisms have been found to be functional, including variations of IL10 and TNF-α described here, validation of their influence on pathogenesis and clinical outcomes in HBV would still be useful. Furthermore, there are no studies exploring the effect of these variants on different responses to HBeAg-positive versus HBeAg-negative disease or with different genotypes of HBV infection.
TLR pathway polymorphisms and response to therapy for HBV
There is very little data examining the influence of genetic variations in TLRs or TLR mediated pathways on outcomes from therapy for HBV. As mentioned, the A-allelic polymorphism of the TNF-α promoter at position 238 has been associated with non-response to lamivudine treatment for chronic HBV in a single study involving Asian patients [77] . This study found no effect from the 308AG variant. There are no other studies of polymorphisms of TLRs, signalling molecules or relevant cytokines and outcomes from therapy for HBV. There is also no published data involving other ethnicities or newer antiviral agents for HBV.
HCV
TLRs and chronic HCV
Innate immune pathways are also crucial for the response to HCV. HCV ligands can directly activate the innate immune system via TLRs to produce inflammatory or antiviral responses. HCV core and NS3 proteins trigger inflammatory cell activation and cytokine induction via TLR2-mediated signalling, whereas TLR3 can sense HCV to induce interferons and limit viral replication [81, 82] . HCV-infected cells can also directly activate plasmacytoid dendritic cells to produce type I interferons via a TLR7-mediated pathway [83] . Furthermore, TLR2 and 4 expression on monocytes is upregulated in patients with chronic HCV with a TLR2-mediated increase in proinflammatory cytokines, such as TNF-α [84] .
However, HCV has also developed strategies targeting specific TLR pathways at several levels to suppress antiviral signalling and promote chronic inflammation. This is a potential mechanism for the virus to evade eradication by the host and sustain chronic infection. Non-structural protein (NS)3 and NS3/4A inhibit TLR3-mediated activation of TRIF and interferon regulatory factor-3 and subsequent up-regulation of interferon-β production [85, 86] . In vitro studies have demonstrated that NS5A can prevent the recruitment of IRAK-1, resulting in reduced MyD88-dependent signalling of TLR2, TLR4, TLR7 and TLR9 pathways [87] . Other ex vivo studies support these findings with impaired cytokine responses in HCV infection to TLR2, TLR4 and TLR9, which appears to specifically involve plasmacytoid dendritic cells [88, 89] . HCV core protein and NS3 may act as TLR2 agonists and produce both pro-and anti-inflammatory cytokines via TLR2/1 and TLR2/6 heterodimer complexes [81, 90] . NS5A can also up-regulate TLR4 expression on hepatocytes and B-cells to increase interferon-β and IL6 production [91] . Furthermore, patients with chronic HCV lose the tolerance to endotoxin and HCV core protein normally seen after repeated stimulation with TLR ligands, which also promotes persistent inflammation [92] .
TLR pathways may also offer novel treatment strategies. For example, 1 week of treatment with the TLR7 agonist isatoribine resulted in a significant reduction of plasma HCV RNA and an increase in markers of antiviral immunity and macrophage activation [93] .
Studies of TLR polymorphisms in chronic HCV have naturally focused on those receptor pathways involved in the immune response to HCV. We describe these in detail below, and Table 1 summarizes the main findings related to TLR polymorphisms in chronic HCV. We also highlight here carriage rates in different ethnic populations, although data for some SNPs is limited in this regard.
TLR2
Although the role of TLR2 in innate immune responses to HCV is well documented, reported analyses of TLR2 polymorphisms in chronic HCV has so far been limited to the post-liver-transplant population in whom recurrent HCV is nearly universal and generally follows an accelerated course [94, 95] . Eid et al. [96] retrospectively examined the association of a common TLR2 SNP (Arg753Gln) and two TLR4 SNPs (Asp299Gly and Thr399Ile) in a cohort of 92 liver transplant patients with chronic HCV with the clinical outcomes of cirrhosis, retransplantation and death. This study reported a significant association between the homozygous TLR2 Arg753Gln polymorphism with allograft failure and mortality after liver transplantation for chronic HCV. The TLR4 polymorphisms studied were not associated with these outcomes. A recent follow-up study by the same group investigated the possible molecular mechanisms for the previous observations regarding TLR2 [97] . It was demonstrated in vitro that human embryonic kidney (HEK)293 cells transfected with these variant TLR2 genes behaved similarly to TLR2-deficient HEK293 cells with significantly less proinflammatory cytokine production and TLR2 gene up-regulation than wild-type HEK293-TLR2 cells in response to HCV core and NS3 protein. This would indicate that the TLR2 Arg753Gln variation is functionally defective, resulting in impaired TLR2-mediated responses to HCV proteins in vitro, and may account for the previously reported clinical observations.
TLR3
Askar et al. [98] examined the association of 2 polymorphisms of the TLR3 gene (rs5743305 within the promoter region and rs3775291 within exon 4) with epidemiological factors and clinical outcomes in chronic HCV infection. These SNPs were not associated with significant clinical parameters or TLR3 gene expression in PBMCs. Patients with the TT variant of the exon 4 SNP showed a tendency towards higher TLR3 gene expression in the liver. This genotype may also confer different susceptibility to subtypes of HCV infection with no TT variants found in patients with HCV genotype 1a infection. The mechanism for this association has not been explored.
TLR4
The association of TLR4 SNPs and HCV has been best studied in relation to the risk of developing advanced fibrosis or cirrhosis. Activation of TLR4 in hepatic stellate cells has previously been shown to promote fibrogenesis via transforming growth factor (TGF)-β signalling pathways [99] . A subsequent mechanistic study has demonstrated that two common co-segregated TLR4 missense variants (T399I, rs4986791 and D299G, rs4986790) confer protection from hepatic fibrosis by reduction of TLR4-mediated inflammatory and fibrogenic signalling and lowering of the apoptotic threshold of activated hepatic stellate cells [100] . In HCV, multiple variants of TLR4 have been associated with the risk of hepatic fibrosis. Initially, a crosssectional genome-wide association study identified a risk genotype of the TLR4 SNP (rs4986791) as one of seven gene variants making up a prognostic signature used to predict the risk of cirrhosis in a large cohort of Caucasian patients [101] . A follow-up study by Li et al. [102] confirmed the importance of TLR4 in modulating fibrosis progression in HCV. This study examined the previously implicated TLR4 locus in detail using dense association testing and reported multiple variants of TLR4 in relatively high linkage disequilibrium with the index SNP (rs4986791) which included the other commonly studied TLR4 SNP (D299G, rs4986790) [102] . This analysis also identified other TLR4 SNPs independently associated with risk of fibrosis although the index SNP (rs4986791) still had the strongest effect. In total, 15 SNPs were identified and grouped into three haplotypes which were significantly associated with risk of fibrosis. This study was again restricted to Caucasian patients. The presence of the TLR4 D299G SNP was less frequent in patients with end-stage liver disease requiring transplantation than donor controls [103] . This is consistent with the genome-wide analysis demonstrating protection from fibrosis progression in chronic HCV with the TLR4 T399I SNP which cosegregates with TLR4 D299G [101, 103] . This effect is presumably related to attenuated TLR4-mediated signalling and cytokine production. By contrast, in liver transplant recipients infected with HCV, TLR4 D299G was significantly associated with long-term graft failure [103] . The association of this loss-of-function TLR4 mutation and worse outcomes following transplantation may provide insight into the altered immunological events leading to recurrent HCV and graft loss in this setting. These findings are in conflict with the previously mentioned study by Eid et al. [96] which found no association with the TLR4 SNPs Asp299Gly and Thr399Ile and graft failure or mortality post transplantation for HCV, although this study had fewer numbers (92 compared with 430) and may have been underpowered to find such an effect [96, 103] .
There have been no reported prospective studies examining the role of TLR4 SNPs in modulating progressive liver fibrosis in chronic HCV. As previously discussed, HCV interacts with TLR4 through complex and multiple pathways but the role of TLR SNPs in altering immunological responses to HCV other than fibrogenesis has not yet been specifically examined.
TLR7
Studies of TLR7 variations suggest that certain functional TLR7 SNPs may alter the natural course of chronic HCV as well as outcomes from interferonbased therapy in a gender-specific manner. An analysis of three more frequently identified TLR7 SNPs and their effect on grade of inflammation and stage of fibrosis on liver biopsy in a large cohort of predominantly German patients with chronic HCV reported that the presence of the c.1-120T>G variant might offer protection from hepatic inflammation and fibrosis with differences being fully attributable to male patients [104] . PBMCs from patients with this allele displayed increased IL6 production in response to stimulation with a TLR7 ligand [104] . A further study by the same group examined the prevalence of the same 3 TLR7 variants in a large cohort of patients with chronic HCV in comparison to patients with other chronic liver diseases and healthy controls, as well their association with response to interferon-α-based treatment [105] . This study reported an over-representation of the c.32A>T allele in patients with chronic HCV, which was statistically significant in females only, whereas the c.2403G>A allele was less prevalent in male patients with chronic HCV. The third variant (c.1-120T>G) was seen more frequently in other liver diseases, but there were no differences observed for HCV patients. Within the group of female HCV patients, the presence of the c.32T allele was found to be independently associated with treatment failure with interferon, defined as virological non-response. This effect was observed irrespective of genotype and persisted after exclusion of non-Caucasian patients, but the overall effect of this SNP on treatment response was small compared to genotype and combination versus monotherapy. The mechanism for the effect of the c.32A>T SNP on the immune and treatment response to HCV is not clear, although this polymorphism has been shown to be functional in patients with HIV with significantly less interferon-α production following TLR7 activation [17] . More recently, this variant was found to be associated with reduced IL29/interferon-λ1 and interferon-λ receptor gene expression but not with hepatic viral load, other HCV induced genes or clinical outcomes in patients with HCV. This might have implications for possible future interferon-λ-based therapies, but the mechanism for these findings has also not been elucidated [106] . The gender-specific differences of TLR7 SNPs and outcomes in chronic HCV are not unexpected given that the TLR7 gene is located on the X-chromosome [107] .
TLR9
There are no published studies investigating any association between TLR9 polymorphisms and HCV.
TLRs and acute HCV
As with acute HBV, most cases of primary HCV infection are asymptomatic and, therefore, much of our knowledge of innate immunological changes in the early phases of HCV infection is based on models using experimentally-infected chimpanzees and small observational studies in high-risk groups, such as healthcare workers with occupational exposure. It has been demonstrated that, unlike acute HBV, acute HCV is characterized by a strong and early immunological response with the induction of type I interferon production and expression of interferon-stimulated genes within the liver, increased peripheral blood HCV RNA levels and increasing alanine aminotransferase levels [108, 109] . It has been suggested that a more vigorous immune response with associated clinical symptoms and jaundice might result in a greater likelihood of spontaneous clearance [110, 111] . However, the HCV-triggered interferon responses seen in acutely infected chimpanzees did not correlate with clinical outcomes with similar findings in animals that cleared the infection and those that developed chronic infection [108] .
The majority of patients with HCV develop persistent infection, which suggests some impairment of the immune response. Adaptive responses, including a robust HCV-specific CD4 + and CD8 + T-cell response, and host factors, including age and gender, have been associated with viral clearance [110] [111] [112] [113] [114] . However, an important role for the innate immune system is also supported by findings that chimpanzees may clear HCV infection without strong and readily detectable HCV-specific T-cell responses and the association of genetic variations in inhibitory NK cell receptors (KIR2DL3) with spontaneous clearance [115, 116] . As previously described, TLRs are an important component of the initial response to viral infections, including activation of interferon signalling pathways, particularly involving TLR3. HCV is able to disrupt TLR-mediated innate immune signalling via several mechanisms in order to evade clearance and promote chronic infection. Therefore, it may be expected that changes in function or expression of TLRs and TLR-mediated pathways, including functionally significant SNPs, could influence the antiviral responses in the early stages of HCV infection. However, there are no human or animal studies examining TLR changes in acute HCV infection specifically. In addition, there are no prospective or retrospective studies of any association between TLR SNPs and outcomes from acute HCV infection, including clearance.
Intracellular pathways and HCV
As with HBV, there have been no reports to date of genetic polymorphisms in intracellular adaptor molecules involved in TLR pathways and any association with HCV.
Cytokines and HCV
It has previously been demonstrated that serum levels of various cytokines including IL4, IL10 and TNF-α are significantly increased in patients with HCV [117, 118] . There has also been significant interest in the possible effect of polymorphisms in cytokines associated with TLR pathway signalling on HCV infection. Outcomes of relevant studies have been summarized in Table 2 . However, as described in detail below, results appear similarly conflicting to those reported with HBV.
Several studies have suggested that SNPs in the TNF-α promoter region may influence outcomes from HCV infection. A recent meta-analysis examining the G308A polymorphism revealed no significant association with susceptibility to HCV in the overall population [119] . There was a possible effect of this SNP in Asian patients although existing studies were insufficiently powered to determine this conclusively. TNF-α G238A and G308A variations have been associated with more advanced fibrosis in both Asian and Caucasian patients and possibly with responses to antiviral therapy in terms of sustained virological response (SVR) rates [120] [121] [122] [123] . A further variant at position 863 has been associated with viral clearance in African American patients compared to the wild-type, which was associated with viral persistence [124] . However, there are several other reports of no significant association between these TNF-α SNPs and clearance, responses to antiviral therapy or histological severity of disease in different ethnic populations [125] [126] [127] [128] [129] [130] .
The role of IL10 polymorphisms in HCV infection also remains to be fully clarified with inconsistent reported results. It has been suggested that there is no significant association between various IL10 promoter gene polymorphisms and severity of liver disease from HCV, clearance or response to antiviral therapy [125, 126, [131] [132] [133] . However, other studies suggest that patients with the 592A and 819T alleles or haplotypes associated with low IL10 production are more likely to respond to antiviral therapy or spontaneously clear infection [130, 134, 135] . This is again inconsistent with other reports, which found that higher production variants have better virological responses to treatment [136] . High production genotypes, such as the 1082GG variant might also be more frequent in patients with HCV than controls, although this has not been confirmed in other studies [137, 138] . These genotypes might also be associated with a lower risk of progression to cirrhosis although this could be specific to females according to one report [71, 138, 139] . These findings contrast with studies in post-transplant cohorts, which suggest that SNPs resulting in low IL10 production are less likely develop recurrent HCV infection and progressive fibrosis [140, 141] .
Morgan et al. [142] examined several SNPs, including IL10 and TNF-α variants in association with response to pegylated interferon and ribavirin in patients who previously failed to respond to therapy (as part of the HALT-C trial). This study involved a large cohort of non-Hispanic Caucasian patients and, although no significant associations were found for individual SNPs and liver fibrosis or response to therapy, homozygosity for an IL10 promoter diplotype (ACC) was associated with a greater likelihood of achieving SVR. The possible influence of ethnicity on the different outcomes in published studies is also highlighted by findings by Oleksyk et al. [143] , who describe an association between IL10 variants and HCV clearance in African Americans but not European Americans.
Another analysis based on the HALT-C patient cohort examined various polymorphisms associated with the interferon-α pathway and response to therapy [144] . This study suggested that although genetic variants in interferon-α receptors and other downstream proteins induced by interferon-α may be significant, the two SNPs examined in the gene for interferon-α were not associated with SVR. This analysis was again restricted to Caucasian patients.
IL6 polymorphisms have also been implicated in response to HCV infection or treatment. It has been suggested that patients with low production IL6 genotypes are more likely to clear infection, whereas high production genotypes are associated with persistent infection [125] . A further study from Europe of the IL6 C174G polymorphism in HCV-HIV-coinfected patients found that patients with a high production genotype were more likely to respond to interferonbased therapy [145] . However, other studies have found no association between this SNP and susceptibility to or clearance of HCV infection [132, 146] . Yee et al. [147] describe an IL6 haplotype including a combination of several SNPs as being associated with reduced chance of achieving SVR with treatment for chronic HCV.
There are fewer studies examining polymorphisms of other cytokines relevant to TLR signalling in relation to HCV. A study from Taiwan found the TNF-α G308A SNP might be significant, but there was no association between an IL4 SNP (C589T) as well as previously discussed IL10 SNPs and chronic HCV, despite these patients having altered serum cytokine levels [118] . There is also some data implicating a role for a functional IL12 polymorphism (1188A/C) with low production genotypes associated with chronic infection while the high production C allele might improve responses to antiviral therapy or confer protection from infection [148] [149] [150] [151] .
The conflicting and inconclusive results might again be related to differences between published studies in ethnicity, sample size, fibrosis stage or other host and viral factors. The functional significance of some cytokine polymorphisms has been questioned and has not been assessed in many of these studies. Cytokine levels and responses may also be altered at various levels and by other pathways apart from TLR signalling; therefore, it is difficult to elucidate the influence of genetic polymorphisms in cytokines on pathogenesis or outcomes in HCV. It is also possible that the balance between pro-and anti-inflammatory cytokine responses is more significant than individual SNPs. There is data to suggest that combinations of genetic variants such as IL10 high production with interferon-γ low production or TNF-α low production genotypes might be associated with better clinical outcomes [138, 152] . Clearly, altered immune responses can influence HCV infection, and genetic variations in cytokines relevant to TLR pathways may contribute. In the future, combinations of cytokine and/or TLR polymorphisms might be used as markers of response to infection.
TLR pathway polymorphisms and response to therapy for HCV As previously described, Schott et al. [105] observed that presence of the variant T allele at the c.32A>T site of the TLR7 gene was predictive of a poor response to interferon-α-based therapy. This effect was specific to females and most pronounced in difficult-to-treat patients, such as genotype 1 or 4 and those treated with monotherapy. Although an independent risk factor for treatment failure in this cohort, the overall influence of this polymorphism was less than other factors such as genotype and the type of treatment. This variant is thought to be associated with reduced function but the mechanism for the effect on treatment response has not been confirmed. The other TLR7 polymorphisms studied (c.1-120T>G and c.2403G>A) were not associated with treatment outcome in this study. Furthermore, there have been no studies examining genetic polymorphisms of other TLRs or relevant intracellular mediators and responses to antiviral therapy for HCV.
As discussed above, there are several reports suggesting genetic variations in TLR-mediated cytokines can influence responses to treatment for HCV. These include possible roles for the TNF-α G308A SNP, high production genotypes of the IL6 C174G SNP and the high production C-allelic variant of the IL12 A1188C SNP with increased virological responses [123, 145, 150] . A combination of several IL6 SNPs has been associated with reduced SVR rates [147] . There is also data indicating IL10 polymorphisms might be significant, although evidence is conflicting with the high production 1082GG genotype as well as low production variants such as 592A, 819T or low production haplotypes/diplotypes being associated with improved responses to antiviral therapy in different studies [130, 134, 136, 142 ]. Yet further studies have found no association between several TNF-α and IL10 polymorphisms and treatment outcomes [126] [127] [128] [129] [130] 133, 135] . A significant role for variants in the gene for interferon-α has also not been demonstrated [144] . Therefore, host immune variation in TLR function and cytokine production may influence responses to antiviral therapy for HCV but their contribution to treatment outcomes remains unclear.
Hepatitis A, D and E viruses
There is data indicating that hepatitis A virus (HAV) is able to evade innate immune responses required for antiviral interferon production with some similar mechanisms to HCV. This includes specific interaction with the TLR3 signalling pathway via reduction of TRIF mediated activation of interferon regulatory factor 3 [153, 154] . The mechanisms by which HCV is able to establish chronic infection, whereas HAV infection is generally self-limiting, are not certain. There have been no reported investigations of polymorphisms in TLR3 or other TLR pathways in HAV infection.
There are also no studies examining the role of TLR expression or TLR polymorphisms in the responses to or outcomes from hepatitis delta virus (HDV) or hepatitis E virus (HEV) infection. There is limited evidence to suggest that immune variations can influence these diseases with polymorphisms in the interferon-γ gene associated with susceptibility to acute HEV infection and variants in the TGF-β1 gene found in patients with HBV or HBV and HDV infection [155, 156] . However, these data are based on relatively small cohorts of Indian patients only, the functional significance of these variations has not been explored and the role of TLR pathways in this situation remains unclear.
Conclusions
The importance of TLR pathways in responses to and outcomes from chronic HBV and HCV infections has been clearly established. It would stand to reason that functional polymorphisms in relevant TLR genes could also have clinical significance and potential utility for predicting disease progression or responses to therapy.
There is a growing body of data, in chronic HCV in particular, suggesting this might be the case with studies implicating various TLR SNPs and clinical outcomes, including protection from hepatic fibrosis, increased risk of recurrent HCV post-liver-transplantation, impaired responses to interferon-based therapy and possibly altered susceptibility to certain viral genotypes.
However, it should be noted that all of the studies of TLR SNPs in HCV have consisted of predominantly Caucasian patient cohorts. It is known that there is significant variability in the prevalence of TLR SNPs in different populations, probably due to evolutionary and environmental pressures. For example, the commonly studied T399I TLR4 SNP is frequently found in Caucasians while the D299G variant is highly prevalent in Africa [157, 158] . By contrast, both these polymorphisms are rare or absent in Asian populations [158] [159] [160] .
Frequencies of TIRAP SNPs also vary in different populations due to selective pressure with the S180L variant found in Caucasians but rarely in Africa [161, 162] .
Studies investigating the role of TLR SNPs in chronic HBV are surprisingly scarce, with a single negative report in an Asian cohort, which might be explained by the lack of the examined SNPs in this population and a small association study in the posttransplant setting.
In addition to polymorphisms in TLRs themselves, genetic variants of signalling molecules involved in TLR pathways and downstream cytokines might also affect the response to HBV and HCV. However, the evidence for SNPs of relevant cytokines influencing these diseases is unclear, with some conflicting evidence. Once again, ethnic differences among other factors might contribute to some of the inconsistent and inconclusive results here. SNPs affecting intracellular TLR pathways have not been specifically examined in relation to HBV or HCV.
Finally, it may be expected that innate immune responses to HDV and HEV might also be influenced by TLR pathways, and it is known that at least HAV can interfere with TLR-mediated signalling. However, the role of genetic polymorphisms of the TLR system has not yet been specifically examined in these other viral hepatitis infections.
The significance of SNPs affecting TLRs and TLR pathways in HBV and HCV, in particular, clearly warrants further investigation including mechanistic and prospective studies. Given the varying prevalence of known TLR SNPs and infection rates of HBV and HCV in different populations, further study should also be directed at different ethnicities and genotypes.
An improved understanding of the role of TLRs and TLR polymorphisms in the pathogenesis of and responses to chronic HBV and HCV might also help elucidate their clinical relevance. TLR ligands for therapeutic and vaccination purposes are already under development and, ultimately, the ability to predict clinical outcomes and specifically target therapies would be of significant interest.
However, it is possible that different genetic markers or combinations of risk variants may be identified as significant in different populations with viral hepatitis. Genome-wide association studies, including the predictive gene signature for cirrhosis risk described here, and recent findings of other predictive factors for outcomes in chronic HCV, such as IL28 polymorphisms, certainly indicate that TLR SNPs might just be part of an increasingly complex picture.
